ArriVent Announces Positive Phase 1b Data For Firmonertinib In NSCLC With EGFR PACC Mutations
10/9 05:42
(RTTNews) - ArriVent BioPharma Inc. (AVBP) announced positive proof-of-concept randomized global Phase 1b FURTHER interim data for first-line firmonertinib monotherapy in patients with non-small cell lung cancer or NSCLC harboring EGFR PACC mutations....